Company intelligence / Profile preview
Concerto Biosciences
Cambridge, Massachusetts, United Statesconcertobio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
First participant dosed in Phase 1 trial of ENS-002 for atopic dermatitis in November 2024. The company anticipates reporting safety and preliminary proof of mechanism data in 2025.
- Therapeutic areas
- GastroenterologyDermatologyWomen's Health
- Modalities
- Live biotherapeutic productsmicrobe-based products
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Partnerships with biotech and biopharma companies (specific names not mentioned)
Beyond the preview
Go deeper on Concerto Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Concerto Biosciences.